What's Hot
View all perspectives
Richard Conway RichardPAConway
2 years 5 months ago
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway RichardPAConway
2 years 5 months ago
Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt
Janet Pope Janetbirdope
2 years 5 months ago
WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP
Richard Conway RichardPAConway
2 years 5 months ago
Dr Terrier @TerrierBen Mepolizumab gives clinical benefit in EGPA in terms of remission at week 36/48 and accrued remission. Benefit irrespective of presence of vasculitic features, ANCA status, clinical features, etc @RheumNow #EULAR2022 POS0836 https://t.co/GHwt1WNZEs
Richard Conway RichardPAConway
2 years 5 months ago
Adami et al Real world fracture prevention with osteoporosis meds. 30% lower risk with bisphosphonate, 60% denosumab, 90% teriparatide. Bisphosphonates only showed effect after 1 year. Not sure I buy it, very different to RCTs. @RheumNow #EULAR2022 OP0239 https://t.co/6qaYAVw73Q https://t.co/bNwWmxxSeF
Richard Conway RichardPAConway
2 years 5 months ago
Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc
David Liew drdavidliew
2 years 5 months ago
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Richard Conway RichardPAConway
2 years 5 months ago
Amigues et al. Zoledronate related ONJ. French pharmacovigilance database. Rare with rheumatic (vs onc) use but higher than with risedronate or alendronate. Incidence 9.6 vs 2 vs 5.1 /100000 @RheumNow #EULAR2022 OP0240 https://t.co/SCYiyJF76S
Richard Conway RichardPAConway
2 years 5 months ago
Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8
Richard Conway RichardPAConway
2 years 5 months ago
Fornaro et al. GISEA registry. No effect of reduced eGFR<60 on drug survival HR 0.9 (95%CI 0.7-1.2) @RheumNow #EULAR2022 POS0634 https://t.co/TjjxgCCz0Z
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Symplur Hashtags healthhashtags
2 years 5 months ago
Top Influencers of #EULAR2022: @RichardPAConway @RheumNow @eular_org @EMEUNET @rheum_cat @ARD_BMJ @ProftDr More 📊 https://t.co/fUfohEZAoX
Janet Pope Janetbirdope
2 years 5 months ago
#ClinicalPearl? #METEOR is a multi-country ~40K database of #rheumatoid arthritis. @eular_org #EULAR2022- found YOUNGER age of onset of RA close to equator, opposite to low Vitamin D if more NORTH /less sun and MORE #multiple #sclerosis. ?From low age at equator OP0035 @RheumNow
Richard Conway RichardPAConway
2 years 5 months ago
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Richard Conway RichardPAConway
2 years 5 months ago
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Poster Hall